《About the sodium ozagrel treatment of acute cerebral infarction 40 cases（关于奥钠治疗急性脑梗死40例）》由会员分享，可在线阅读，更多相关《About the sodium ozagrel treatment of acute cerebral infarction 40 cases（关于奥钠治疗急性脑梗死40例）（6页珍藏版）》请在金锄头文库上搜索。
1、1About the sodium ozagrel treatment of acute cerebral infarction 40 casesAuthor: Wang Hui high of Jinxiang supplier Lai Wang Jingjing Keywords ozagrel Keywords ozagrel sodium acute cerebral infarction From January to December 2004 apply ozagrel sodium treatment of 40 cases of acute cerebral infarcti
2、on, and achieved satisfactory results, are as follows. 1 Materials and Methods 1.1 General Information Selected cases were Department of Binzhou Medical College Hospital Department of Neurology, hospitalized patients, a total of 80 cases were randomly divided into treatment group (40 cases) and cont
3、rol group (40 cases), clinical diagnosis are in line with the 1995 Fourth National Cerebrovascular Disease meeting the standards established 1, and confirmed by CT for cerebral infarction two groups of patients had no serious heart and liver kidney disease, bleeding tendency, recent surgery or the u
4、se of anti-platelet aggregation 2drugs onset within 72 h, exclude TIA. treatment group, 23 males, female l7 patients, aged 42 to 75 years old, with an average age of 62.5 years, the head CT showed multiple lacunar infarction eight cases, one side of the basal ganglia, the corona radiata infarction 1
5、7 cases, large area of infarction in 10 cases, 22 cases with hypertension, diabetes, three cases of the control group of 40 patients, 26 males and 14 females, aged 42 to 75 years, with an average age of 63.5 years, the head CT showed multiple cavity gap cerebral infarction in 10 cases, one side of t
6、he basal ganglia, the corona radiata infarction in 27 cases, 8 cases of massive cerebral infarction, and hypertension in 30 cases, 4 cases of diabetes. Both groups were gender, age, severity of the disease, merge There were no significant differences in disease comparable. 1.2 Exclusion criteria wer
7、e not selected for one of the following circumstances: the hemorrhagic infarction massive cerebral infarction deep coma with bleeding tendency, , serious heart, lung, liver, renal insufficiency, serious high blood pressure, systolic 3blood pressure 200 mm Hg. 1.3 treatment groups were routine applic
8、ation of blood circulation drugs, brain cell activator, anti-free radical agents, calcium antagonists, depending on condition applied as appropriate dehydrating agent. Added to 250 ml of normal saline intravenous treatment group on the basis of application Hainanbikai Pharmaceutical Co ozagrel sodiu
9、m 80 mg, 2 times a day, two weeks for a course of treatment, medication monitoring of blood during clotting three, liver and kidney function. 2 Results The 2.l efficacy standards Efficacy standards developed in accordance with the 1995 fourth cerebrovascular disease conference 1, is divided into Bas
10、ic cured: impairment score decreased by 91% to 100%, 0 degree of disability, significant progress: the score was reduced by 46% to 90% degree of disability grades 1 to 3, progress: score decreased by 18% to 45% of unchanged: score less than 17% decrease or increase, worse: ratings increased by 18% 4
11、or more. 2.2 The effects of Links to free papers Download Center http:/after 1 month of treatment efficacy evaluation of the two groups of patients are shown in Table l. Table 1 Comparison of two groups (omitted) 2.3 side effects Occurrence of hemorrhagic infarction the oozing type 2 cases of upper
12、gastrointestinal bleeding in 4 patients, the treatment group and the control group l cases of upper gastrointestinal bleeding. Medication before and after routine blood, liver and kidney function, blood clotting three no significant change. 3 Discussion Increased blood viscosity and platelet aggrega
13、tion as a major cause of cerebral infarction. Plays a very important role in platelet aggregation in thrombosis, platelet aggregation by thromboxane A2 (TXA2) and prostacyclin (PGI2) levels, TXA2 strongly promote platelet aggregation and contraction of vascular thrombosis, PGI2 strongly inhibit thro
14、mbosis, prompting thrombolytic sodium ozagrel 5strong TXA2 synthetase inhibitors 2, can be effective in blocking the formation of TXA2 synthase, while promoting PGI2 synthesis the production of enzymes, which strongly inhibit platelet aggregation, improve cerebral circulation, increase penumbra arou
15、nd the infarct zone of the blood supply, promote functional recovery of nerve cells. while ozagrel sodium dilation of blood vessels, increase blood flow, reduce blood viscosity, improve tissue microcirculation and energy metabolism, the embolization recanalization The data showed that between the tw
16、o groups significant efficiency and total efficiency were significantly different, suggesting ozagrel sodium in the treatment of acute cerebral infarction significantly but we found the cause hemorrhagic infarction and upper gastrointestinal bleeding side effects, due to small number of cases failed to between the two groups were analyzed, we found that these side effects occurred in massive cerebral infarction patie
